• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[RU 486及其活性代谢产物在人体中的药代动力学]

[Pharmacokinetics of RU 486 and its active metabolites in humans].

作者信息

Földesi I, Falkay G, Kovács L

机构信息

Szent-Györgyi Albert Orvostudományi Egyetem Szülészeti és Nögyógyászati Klinika, Szeged.

出版信息

Acta Pharm Hung. 1994 Jan;64(1):17-21.

PMID:8023681
Abstract

The pharmacokinetics of RU 486 and its active metabolites were studied in 31 women who received a single oral dose of 200 mg (n = 9), 400 mg (n = 10) or 600 mg (n = 12) of RU 486 for termination of an early unwanted pregnancy. The serum levels were measured within 48 hours after the intake by radioligand binding assay using human myometrial cytosolic progesterone receptor as binding protein. The assay is based on the competitive replacement of 3H-ORG-2058 by the active molecular fraction of RU 486 present in the serum. The results were expressed as RU 486 equivalent. It was found that pharmacokinetics of the RU 486 equivalent followed two-compartment open model. The pharmacokinetic parameters were calculated by MEDUSA computer programme. Rapid absorption and distribution was followed by relatively slow elimination. The elimination half-life ranged between 80-90 hours. No significant difference was found between the parameters of the absorption distribution and elimination processes of three different doses. Thus, the RU 486 equivalent followed first-order kinetic. Peak serum concentrations were reached within 1-2 hours after the ingestion of the drug. Significant differences were found between 200 and 600 mg doses in the peak plasma values (p < 0.05) and in the areas under the curve (p < 0.01). However, these differences were not directly proportional to the increase of the dose.

摘要

在31名接受单次口服200毫克(n = 9)、400毫克(n = 10)或600毫克(n = 12)RU 486以终止早期意外妊娠的女性中,研究了RU 486及其活性代谢物的药代动力学。在服药后48小时内,使用人子宫肌层胞质孕酮受体作为结合蛋白,通过放射性配体结合测定法测量血清水平。该测定基于血清中存在的RU 486活性分子部分对3H-ORG-2058的竞争性置换。结果以RU 486当量表示。发现RU 486当量的药代动力学遵循二室开放模型。药代动力学参数通过MEDUSA计算机程序计算。快速吸收和分布之后是相对缓慢的消除。消除半衰期在80 - 90小时之间。三种不同剂量的吸收、分布和消除过程参数之间未发现显著差异。因此,RU 486当量遵循一级动力学。服药后1 - 2小时内达到血清峰值浓度。200毫克和600毫克剂量之间在血浆峰值(p < 0.05)和曲线下面积(p < 0.01)方面存在显著差异。然而,这些差异与剂量增加并非直接成比例。

相似文献

1
[Pharmacokinetics of RU 486 and its active metabolites in humans].[RU 486及其活性代谢产物在人体中的药代动力学]
Acta Pharm Hung. 1994 Jan;64(1):17-21.
2
[Radioreceptor assay for determination of the anti-progestogen, RU-486 and its active metabolites in the blood].[用于测定血液中抗孕激素RU-486及其活性代谢物的放射受体分析法]
Acta Pharm Hung. 1992 Nov;62(6):271-7.
3
Determination of RU486 (mifepristone) in blood by radioreceptorassay; a pharmacokinetic study.
Contraception. 1996 Jul;54(1):27-32. doi: 10.1016/0010-7824(96)00116-3.
4
Binding activity of 5alpha-reduced gestagens to the progestin receptor from African elephant (Loxodonta africana).5α-还原孕激素与非洲象(Loxodonta africana)孕激素受体的结合活性。
Gen Comp Endocrinol. 1997 Feb;105(2):164-7. doi: 10.1006/gcen.1996.6813.
5
Pharmacokinetic properties of the antiglucocorticoid and antiprogesterone steroid RU 486 in man.
J Pharmacol Exp Ther. 1987 May;241(2):401-6.
6
Pharmacokinetics and metabolism of RU 486.
J Steroid Biochem. 1987;27(4-6):859-63. doi: 10.1016/0022-4731(87)90160-9.
7
A pharmacokinetic study with a low-dose oral contraceptive containing 20 microg ethinylestradiol plus 100 microg levonorgestrel.一项关于含有20微克炔雌醇加100微克左炔诺孕酮的低剂量口服避孕药的药代动力学研究。
Eur J Contracept Reprod Health Care. 2002 Jun;7(2):79-90.
8
Antiprogesterone steroid RU486. Pharmacokinetics and receptor binding in humans.抗孕激素甾体RU486。人体药代动力学及受体结合情况。
Acta Obstet Gynecol Scand. 1990;69(4):357-8. doi: 10.3109/00016349009036163.
9
Pharmacokinetics of the progesterone antagonist 17 beta-hydroxy-11 beta-(4-dimethylaminophenyl)-17 alpha-(1-propynyl) estra-4,9-dien-3-one in the rabbit.孕酮拮抗剂17β-羟基-11β-(4-二甲基氨基苯基)-17α-(1-丙炔基)雌甾-4,9-二烯-3-酮在兔体内的药代动力学
Arzneimittelforschung. 1986 Jun;36(6):936-8.
10
Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.类风湿关节炎患者同时使用甲氨蝶呤时依那西普的药代动力学未改变。
J Clin Pharmacol. 2004 Nov;44(11):1235-43. doi: 10.1177/0091270004268049.